

Around the world of U.S. healthcare in 360 words or less

Center for Healthcare Regulatory Insight

November 12, 2021 | Issue 197

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

Subscribe here 🧹

Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized <u>COVID-19 news for the week in this special supplement</u>.

0



Healthcare regulatory news

CMS rescinded the Medicare Coverage of Innovative Technology final rule.

HHS <u>named 200 hospital participants</u> for the <u>HHS Maternal Morbidity</u> and <u>Mortality Data and Analysis Initiative</u> to improve maternal/infant health outcomes... CMS increased funding for Basic Health Program insurance coverage for 1.1 million <u>New York</u> and <u>Minnesota</u> recipients.

OMB is reviewing an <u>FDA proposed rule establishing federal standards</u> for licensing prescription drug wholesale distributors/third-party logistics providers and the <u>2023 ACA exchanges proposed rule</u>.

0



Healthcare law and policy news

President Biden nominated Robert Califf as FDA Commissioner.

Supreme Court <u>will hear a dispute over the scope of federal laws</u> <u>governing</u> employer-sponsored health plan coverage of end-stage renal disease care... Two <u>federal courts diverged</u> on <u>whether the federal</u> <u>government can require</u> pharmaceutical manufacturers to resume passing on 340B discounts to contract pharmacies... Oklahoma Supreme Court <u>overturned a \$465M judgement</u> against Johnson & Johnson (J&J) over its role in the opioid epidemic.

Justice Department is <u>investigating Oak Street Health</u> for possible False Claims Act violations related to <u>third-party marketing agents and</u> <u>"free transportation"</u>... Two Sun Pharmaceuticals subsidiaries will <u>pay</u> <u>\$85M to settle generic pharmaceutical</u> pricing antitrust litigation... Kaleo will <u>pay \$12.7M to resolve False Claims Act allegations</u> related to its opioid overdose treatment.

GE will <u>split into three public companies</u>, including GE Healthcare... J&J will <u>split into two public companies</u>: consumer goods and prescription drug/medical devices... Anthem <u>will acquire Integra</u> <u>Managed Care</u>... Tenet will <u>acquire SurgCenter Development (\$1.2B)</u>, gaining ownership interest in 92 ambulatory surgery centers... Blackstone will <u>invest upwards of \$250M in Autolus Therapeutics</u> to fund development of a leukemia therapy.

Biogen is <u>investigating the death of a 75-year-old patient</u> who took Aduhelm... Roche said <u>its Alzheimer's drug, if approved, would be</u> priced competitively, likely below the cost of Aduhelm.

A KFF survey found the <u>cost of employer-sponsored family health</u> <u>insurance coverage</u> increased 4% to \$22,221; 95% of large employers <u>cover telehealth</u> in their largest health plan... A *JAMA* study found <u>hospitals are charging private insurers "considerable markups"</u> on commonly used Part B drugs, in some cases several times Medicare prices... Lown Institute estimated <u>Medicare could save \$8B/year if all</u> <u>hospitals achieved the same outcomes and cost efficiency</u> as the 750 top performing hospitals. 0

Questions or comments, please send to <u>ushcinsight@kpmg.com</u>.

Succeeding in the new reality

Visit the COVID-19 resource center for KPMG analysis, insights, and perspectives.

kpmg.com/socialmedia



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



COVID-19 News Supplement

Center for Healthcare Regulatory Insight



COVID-19 by the Numbers

There have now been <u>roughly 46.9 million confirmed COVID-19 cases</u> in the US, with a death toll of nearly 760,000... The country averaged <u>roughly 74,000 new cases per day</u> over the past week, up 4% from the preceding two weeks.

434 million COVID-19 <u>vaccine doses have been administered</u> in the US (roughly 1.31 million/day over the past week)... More than 224.6 million Americans (<u>79% of Americans 12 and older</u>) have received at least one COVID-19 vaccine dose; over 194 million Americans are fully vaccinated (68.5% of Americans 12 and older); 26 million Americans have received a booster dose... The White House said roughly <u>900,000</u> children under age 12 received a vaccine in the first week of eligibility, with another 700,000 scheduled to receive their first dose.

Executive and Administrative Action

The Biden Administration will invest \$650 million to ramp up domestic manufacturing of COVID-19 rapid diagnostic tests... The White House announced \$785 million in American Rescue Plan funding to combat health inequities in communities most impacted by the pandemic.

The Administration also announced efforts to support global vaccination, including <u>donating 1.5 million</u> <u>doses of Johnson & Johnson's vaccine</u> to COVAX for people in conflict zones and other humanitarian settings, a <u>COVID-19 data tracker</u> built by the World Health Organization and other international organizations, and a <u>public-private partnership to assist with vaccine campaigns</u>.

The Administration will also make FEMA pandemic support <u>available to states, tribes, and territories</u> <u>through April 1, 2022</u>.

An <u>appeals court suspended the Biden Administration's COVID-19 vaccine requirement</u> for private employers with over 100 employees... the White House urged businesses to <u>move forward with the</u> <u>vaccine requirement for employees</u>, while expressing optimism that the requirements would ultimately stay in effect... Surgeon General Vivek Murthy also <u>defended the mandate as an "appropriate and</u> <u>necessary"</u> step to combat the pandemic... Meanwhile, <u>10 states sued to halt</u> the Administration's vaccine <u>requirement for healthcare workers</u> and the American Medical Association <u>defended the</u> <u>requirement in a friend-of-the-court</u> brief.

FCC <u>awarded \$42.16 million in funds</u> to 75 additional applicants in the COVID-19 Telehealth Program, bringing the total awarded to \$166.13 million.

Healthcare Law, Business, and Policy News

Ellume will <u>recall 2.2 million at-home COVID-19 tests</u> due to the risk of returning false positives. A KFF <u>survey found that 78% of adults had heard</u> at least one of eight false statements about COVID-19 and either believe it to be true or were unsure what to think... An Axios/Ipsos survey found that <u>55% of Americans believe returning to normal life is only a small risk or no risk at all</u>, up from just 40% in late-August.

Surveillance, Testing, and Treatment

Pfizer-BioNTech asked the FDA to <u>authorize a booster dose of their COVID-19 vaccine for anyone 18 and</u> <u>older</u>... Pfizer's CEO reiterated his belief that <u>COVID-19 boosters could be needed annually</u>.

Moderna and the National Institutes of Health are <u>disputing the role that NIH researchers played in</u> <u>development of Moderna's COVID-19 vaccine</u> and whether federal researchers should be listed on the "principal patent application"... NIH Director Francis Collins said that NIH <u>scientists played "a major role"</u> <u>in development of the vaccine</u> and the agency plans to defend its claim as co-owner of vaccine patents.

AstraZeneca is creating <u>a separate division within the company for vaccines and antibody therapies</u> in order to better focus COVID-19-related efforts.

Regeneron reported a <u>single dose of its mAb cocktail reduced the risk of contracting</u> COVID-19 by 81.6% in the two-to-eight-months period following the drug's administration in a late-stage trial.

Pfizer plans to <u>submit data on its experimental COVID-19 antiviral pill to the FDA</u> by November 25 with hopes of receiving emergency use authorization... according to President Biden, the federal government <u>purchased "millions of doses"</u> of the pill, pending FDA authorization.

Merck reported that the federal government will <u>buy another 1.4 million courses of its COVID-19</u> <u>antiviral pill molnupiravir</u> developed with Ridgeback, bringing the total doses purchased to 3.1 million... The EU is negotiating with Merck and Pfizer <u>over possible contracts to supply their respective antiviral</u> <u>pill</u> to member states; discussions with Merck have progressed further because the company has already submitted data to the European Medicines Agency.